Individuals who have elevated levels of oxidative stress
The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)
By gently stretching the spine in a controlled way, decompression therapy may help: reduce nerve compression improve disc hydration decrease mechanical stress on the disc This is why it is sometimes used for conditions such as: herniated discs bulging discs sciatica degenerative disc disease Treatment recommendations always depend on an individual evaluation and diagnosis
PubMed laboratory research record [PMID: 17112680] PubMed record related to this compound for laboratory literature review
Side effects appear to be infrequent and mild in most reported cases, and may include: Temporary injection site reactions (with subcutaneous administration) Mild headache in some individuals Vivid dreams often considered a sign of enhanced REM sleep activity Occasional mild gastrointestinal discomfort DSIP does not appear to suppress respiratory function or cause the cognitive impairment sometimes associated with sedative-hypnotic drugs
Anti-inflammatory cytokine expression: The peptide shifts cytokine profiles toward anti-inflammatory patterns, reducing chronic inflammation that delays healing